Insider sales are too small to warrant concern. Monitor for any larger insider transactions in the coming weeks, particularly if accompanied by material news. The earnings release itself is the more relevant event for traders.
RARE drugs
RARE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $24.77entry
- T+1 · 7mo ago +0.16%α +0.50% · $24.81
- T+5 · 6mo ago +5.49%α +3.14% · $26.13
- T+20 · 6mo ago −7.75%α −13.04% · $22.85
- T+60 · 4mo ago +4.88%α +1.82% · $25.98
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Ultragenyx insiders (CFO and Chief Medical Officer) sold a combined $125K in open-market transactions over the past week, representing just 0.005% of market cap. The sales followed the company's earnings release and are negligible relative to company size, indicating routine portfolio management rather than a negative signal.
Key Financial Metrics
Key Facts
- CFO Howard Horn sold 4,683 shares at ~$24.90 for $117K on May 1.
- Chief Medical Officer Eric Crombez sold 344 shares at $24.96 for $9K on May 5.
- Total insider sales of $125K represent 0.005% of RARE's $2.5B market cap.
- Sales occurred within one day of the company's May 5 earnings release (8-K Item 2.02).
Financial Impact
Trivial insider selling of $125K total, immaterial to company valuation.
Risk Factors
- No material risk from these sales; however, continued insider selling at larger volumes could signal management sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RARE-1778093500730 |
Track record
22 reports on RARE
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers